Delphine Davan
Director of Communications, IMV Inc.
+1 514 968 1046
Questions for our Media Relations team can be submitted through the form below.
IMV Inc. is a clinical-stage immuno-oncology company dedicated to making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV's proprietary drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. Lead product candidate DPX-Survivac is currently being evaluated in several clinical trials in advanced ovarian cancer in combination with other innovative immunotherapy agents.
© 2018 IMV Inc. All rights reserved.
130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4
© 2018 IMV Inc. All rights reserved.